Ipsen: Morgan Stanley raises target price
(CercleFinance.com) - Morgan Stanley reiterates its "overweight" recommendation on the share of French pharmaceutical company Ipsen, while raising its corresponding target price from 90 euros to 101 euros, meaning upside potential of 15%.
"Our deep-dive into Ipsen's oncology assets has revealed material upside to sales forecasts in 2024 and beyond," the broker says, which raises its forecasts for Cabometyx.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"Our deep-dive into Ipsen's oncology assets has revealed material upside to sales forecasts in 2024 and beyond," the broker says, which raises its forecasts for Cabometyx.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.